S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Silk Road Medical Stock Forecast, Price & News

+1.71 (+4.17%)
(As of 12/6/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
306,660 shs
Average Volume
327,610 shs
Market Capitalization
$1.49 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SILK News and Ratings via Email

Sign-up to receive the latest news and ratings for Silk Road Medical and its competitors with MarketBeat's FREE daily newsletter.

Silk Road Medical logo

About Silk Road Medical

Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$75.23 million
Book Value
$2.53 per share


Net Income
$-47.37 million
Pretax Margin




Free Float
Market Cap
$1.49 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.96 out of 5 stars

Medical Sector

679th out of 1,394 stocks

Surgical & Medical Instruments Industry

76th out of 126 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Silk Road Medical (NASDAQ:SILK) Frequently Asked Questions

Is Silk Road Medical a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Silk Road Medical stock.
View analyst ratings for Silk Road Medical
or view top-rated stocks.

How has Silk Road Medical's stock been impacted by COVID-19 (Coronavirus)?

Silk Road Medical's stock was trading at $37.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SILK stock has increased by 15.0% and is now trading at $42.71.
View which stocks have been most impacted by COVID-19

When is Silk Road Medical's next earnings date?

Silk Road Medical is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Silk Road Medical

How were Silk Road Medical's earnings last quarter?

Silk Road Medical, Inc (NASDAQ:SILK) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.09. The business had revenue of $24.70 million for the quarter, compared to analysts' expectations of $26.03 million. Silk Road Medical had a negative net margin of 54.99% and a negative trailing twelve-month return on equity of 52.81%. During the same period in the previous year, the company posted ($0.31) EPS.
View Silk Road Medical's earnings history

What guidance has Silk Road Medical issued on next quarter's earnings?

Silk Road Medical updated its FY 2021 earnings guidance on Tuesday, December, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $99 million-$102 million, compared to the consensus revenue estimate of $103.23 million.

What price target have analysts set for SILK?

4 brokers have issued 1 year price targets for Silk Road Medical's shares. Their forecasts range from $50.00 to $66.00. On average, they expect Silk Road Medical's stock price to reach $57.75 in the next twelve months. This suggests a possible upside of 35.2% from the stock's current price.
View analysts' price targets for Silk Road Medical
or view top-rated stocks among Wall Street analysts.

Who are Silk Road Medical's key executives?

Silk Road Medical's management team includes the following people:

What other stocks do shareholders of Silk Road Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), Honeywell International (HON), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

When did Silk Road Medical IPO?

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

What is Silk Road Medical's stock symbol?

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Who are Silk Road Medical's major shareholders?

Silk Road Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (9.97%), Wasatch Advisors Inc. (9.61%), Alliancebernstein L.P. (8.43%), BlackRock Inc. (7.32%), Bamco Inc. NY (5.01%) and Kayne Anderson Rudnick Investment Management LLC (3.76%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Andrew S Davis, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Pincus & Co Warburg and Richard Ruedy.
View institutional ownership trends for Silk Road Medical

Which major investors are selling Silk Road Medical stock?

SILK stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Victory Capital Management Inc., Deerfield Management Company L.P. Series C, Peregrine Capital Management LLC, Granahan Investment Management Inc. MA, TimesSquare Capital Management LLC, M&G Investment Management Ltd., and Next Century Growth Investors LLC. Company insiders that have sold Silk Road Medical company stock in the last year include Andrew S Davis, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, and Richard Ruedy.
View insider buying and selling activity for Silk Road Medical
or view top insider-selling stocks.

Which major investors are buying Silk Road Medical stock?

SILK stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Sectoral Asset Management Inc, Wasatch Advisors Inc., Jennison Associates LLC, Granite Investment Partners LLC, Thornburg Investment Management Inc., Bamco Inc. NY, and American Century Companies Inc..
View insider buying and selling activity for Silk Road Medical
or or view top insider-buying stocks.

How do I buy shares of Silk Road Medical?

Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silk Road Medical's stock price today?

One share of SILK stock can currently be purchased for approximately $42.71.

How much money does Silk Road Medical make?

Silk Road Medical has a market capitalization of $1.49 billion and generates $75.23 million in revenue each year. The company earns $-47.37 million in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does Silk Road Medical have?

Silk Road Medical employs 281 workers across the globe.

What is Silk Road Medical's official website?

The official website for Silk Road Medical is www.silkroadmed.com.

Where are Silk Road Medical's headquarters?

Silk Road Medical is headquartered at 1213 INNSBRUCK DR., SUNNYVALE CA, 94089.

How can I contact Silk Road Medical?

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at (408) 720-9002, via email at [email protected], or via fax at 408-720-9013.

This page was last updated on 12/7/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.